Healthcare Sys & Biz

Rheumatology care: Is lower drug cost worth limited access?

A new CMS drug pricing rule could lead to unintended consequences for patients with rheumatic diseases, according to the American College of Rheumatology.

Dialysis costs: Medicare as primary payer could save $1 billion

The Medicare Secondary Payer Act modestly reduced federal dialysis spending, but only when private prices were less than 3.05 times Medicare rates.

Your white coat isn't the authority it once was. What is?

The traditional white coat, once a universal symbol of medical authority, has seen its prominence wane in clinical settings, replaced by scrubs and the simple passage of time.

Why vaccine skepticism thrives despite overwhelming data

Vaccine skepticism often thrives on narrative structures that bypass scientific evidence, creating powerful, emotionally resonant messages that challenge public health efforts.

ICD-11: What European GPs need to know about the new classification system

The ICD-11 system introduces significant changes to disease classification, impacting coding for conditions like hidradenitis suppurativa and neonatal encephalopathy.

Why patient-reported outcomes rarely make it onto drug labels

Despite their clinical relevance, patient-reported outcomes (PROs) face significant hurdles in gaining regulatory approval for inclusion on drug labels.

Do patient-reported outcomes actually improve survival?

Routine symptom monitoring with patient-reported outcomes does not improve survival, despite its perceived benefits in quality of life.

How regulatory guidance on real-world evidence changed drug submissions

Regulatory bodies have refined their expectations for real-world evidence, pushing sponsors to integrate these data earlier and more strategically into drug development programs.

Do biosimilar switching studies show any real efficacy or immunogenicity signal?

Biosimilar switching studies consistently show no significant differences in efficacy or immunogenicity compared to reference biologics.